Renub

    Europe Breast Cancer Screening Market, Size, Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis

    Excel: 8 Hours
    PDF: 24 Hours
    Jul 2023
    Pages: 240

    Europe Breast Cancer Screening Market Outlook

    Europe Breast Cancer Screening Market will reach US$ 433.45 Million in 2028, according to Renub Research. Breast cancer is the leading form of cancer affecting women in Europe, with approximately 400,000 new cases annually and resulting in 100,000 fatalities. This type of cancer originates from malignant tumors that develop in breast cells. In rarer cases, breast cancer can also begin in the stromal tissues, encompassing the fatty and fibrous connective tissues of the breast. In 2020, breast cancer constituted 13.3% of all newly diagnosed cancer cases in the EU-27 countries, making it the most prevalent cancer type. Moreover, it accounted for 28.7% of all new cancer cases detected in women.

    The growing awareness regarding the significance of breast cancer screening among women in Europe has contributed to an increased demand for screening services. This heightened awareness is the result of various initiatives including campaigns, educational programs, and advocacy groups that aim to encourage women to undergo screening. The aging population has also played a role in driving the demand for breast cancer screening, as the likelihood of breast cancer diagnosis is higher in older women.

    To address this, European governments have implemented screening programs and policies to enhance access to breast cancer screening, particularly for underserved populations. Advancements in technology have led to the development of more precise and minimally invasive screening methods, such as digital mammography, breast ultrasound, and magnetic resonance imaging (MRI), which have significantly improved the detection of breast cancer.

    europe-breast-cancer-screening-market

    The Europe Breast Cancer Screening Market is expected to experience a growth rate of approximately 3.19% from 2022 to 2028

    In several European countries, comprehensive strategies involving Patient Support Programs and awareness campaigns have been implemented to promote early detection and treatment of breast cancer. Notably, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumabderuxtecan) has received approval in the European Union (EU) as a standalone therapy for adult patients with unrespectable or metastatic HER2-positive breast cancer, who have previously undergone one or more anti-HER2-based treatment regimens.

    Enhertu is an innovative antibody-drug conjugate (ADC) that specifically targets HER2 and is jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. The European market has experienced revenue growth due to the approval of novel treatment approaches and significant investments in Research and Development by key industry players. In 2022, the Europe Breast Cancer Screening Market was valued at approximately US$ 359.1 Million, reflecting the substantial size of the industry within the region.


    Germany commitment to improving breast cancer outcomes continues to drive its success in this vital healthcare sector

    By Country, Europe Breast Cancer Screening Market is segmented into United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway and Netherlands. Germany holds the largest market share in the Breast Cancer Screening Market. The country's prominence can be attributed to several factors such as its robust healthcare infrastructure, well-established screening programs, and a proactive approach towards breast cancer awareness and early detection. Germany's emphasis on regular screening, coupled with advancements in technology and access to quality healthcare services, has contributed to its leading position in the market. Ongoing research and development activities, collaborations between academic institutions and industry players, and government initiatives further support Germany's dominance in the Breast Cancer Screening Market.


    Spain innovative healthcare services drive rapid expansion, contributing significantly to enhancing breast cancer diagnosis and improving outcomes with a focus on quality

    By Mammography Screening, Europe Breast Cancer Screening Market is classified into United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway and Netherlands. Spain is emerging as the fastest-growing market in the Breast Cancer Mammography Screening industry. The country's remarkable growth can be attributed to several factors. Spain has made substantial investments in advanced mammography technologies, ensuring accurate and early detection of breast cancer. The Spanish healthcare system has implemented comprehensive screening programs and initiatives, leading to increased awareness and participation among women.

    Moreover, Spain's commitment to research and development, along with collaborations between healthcare institutions and industry leaders, has propelled the growth of the Breast Cancer Mammography Screening industry. With a focus on innovation and quality healthcare services, Spain is set to maintain its rapid expansion and make significant contributions to improving breast cancer diagnosis and outcomes.


    United Kingdom is emerging as a rapidly growing market in the Breast Cancer MRI Screening industry in upcoming years

    MRI Screening, Europe Breast Cancer Screening Market is divided into United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway and Netherlands. The United Kingdom (UK) is emerging as a rapidly growing market in the Breast Cancer MRI Screening industry. The country's significant progress can be attributed to several key factors. The UK has made substantial investments in state-of-the-art MRI technology, enabling precise and detailed imaging for breast cancer diagnosis.

    Moreover, the UK's comprehensive healthcare system, combined with its strong emphasis on early detection and screening programs, has increased awareness and participation among women. The government's proactive approach, along with collaborations between healthcare institutions and industry leaders, has further fueled the growth of the Breast Cancer MRI Screening industry in the UK. With a focus on continual advancements and quality patient care, the UK is poised to continue its rapid expansion and make noteworthy contributions to improving breast cancer diagnosis and treatment outcomes.


    Germany is playing a pivotal role in improving breast cancer diagnosis and patient outcomes through its expanding ultrasound screening market

    Ultrasound Screening, Europe Breast Cancer Screening Market is sub-segmented into United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway and Netherlands. Germany ultrasound screening market in the Breast Cancer industry is experiencing notable growth. The Germany advancements in ultrasound technology, coupled with its robust healthcare system, have contributed to this positive trend. Germany emphasis on early detection and comprehensive screening programs has led to increased adoption of ultrasound as a reliable diagnostic tool for breast cancer. The country well-established infrastructure, including advanced imaging facilities and trained healthcare professionals, has further supported the growth of the ultrasound screening market. Germany commitment to research and development, along with collaborations between academia and industry, has facilitated continuous innovation in ultrasound technologies.


    Key Player

    In the Europe Breast Cancer Screening Market, prominent players such as AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, and GlaxoSmithKline plc hold significant positions. These companies play a crucial role in driving advancements, innovation, and providing effective solutions for breast cancer screening across the region. Their significant presence reflects their commitment to improving breast cancer detection and contributing to better patient outcomes.

    Renub Research report titled “Europe Breast Cancer Screening Market by type (Mammography Screening, MRI Screening, and Ultrasound Screening) by Country (United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway and Netherlands) by Company Analysis (AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, and GlaxoSmithKline plc)” provides a complete analysis of Europe Breast Cancer Screening Industry.

    europe-breast-cancer-screening-market-share

    Types – Market has been covered from 3 viewpoints

    1.    Mammography Screening
    2.    MRI Screening
    3.    Ultrasound Screening


    Countries – 8 European Country Breast Cancer Screening Market has been Covered

    1.    United Kingdom
    2.    France
    3.    Germany
    4.    Italy
    5.    Spain
    6.    Switzerland
    7.    Norway
    8.    Netherlands


    Company Insights:

    •    Overview
    •    Recent Development
    •    Sales Analysis


    Companies Covered in the Report:

    1.    AstraZeneca
    2.    Novartis
    3.    Sanofi
    4.    Pfizer
    5.    Bayer AG
    6.    GlaxoSmithKline plc


    Report Details:

    Report Features Details
    Base Year 2022
    Historical Period 2018 - 2022
    Forecast Period 2023 - 2028
    Market US$ Million
    Segment Covered Types, Countries (United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway and Netherlands)
    Companies Covered AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, and GlaxoSmithKline plc
    Customization Scope 20% Free Customization
    Post-Sale Analyst Support 1 Year (52 Weeks)
    Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request)

    1.    Introduction

    2.    Research Methodology

    3.    Executive Summary

    4.    Market Dynamics

    4.1    Growth Drivers
    4.2    Challenges


    5.    Porter’s Five Forces

    5.1    Bargaining Power of Buyer
    5.2    Bargaining Power of Supplier
    5.3    Threat of New Entrants
    5.4    Rivalry among Existing Competitors
    5.5    Threat of Substitute Products


    6.    SWOT Analysis

    6.1    Strengths
    6.2    Weaknesses
    6.3    Opportunities
    6.4    Threats


    7.    Population Analysis - Europe Breast Cancer Screening Market

    7.1    Europe Breast Cancer Mammography Screening Population
    7.2    Europe Breast Cancer MRI & Ultrasound Screening Population


    8.    Europe Breast Cancer Screening Market Analysis

    8.1    Europe Breast Cancer Screening Market

    8.1.1    Mammography Screening Market
    8.1.2    MRI Screening Market
    8.1.3    Ultrasound Screening Market


    9.    Population Share Analysis - Europe Breast Cancer Screening

    9.1    Mammography Screening Population Share
    9.2    MRI & Ultrasound Screening Population Share


    10.    Share Analysis - Europe Breast Cancer Screening Market

    10.1    Europe Breast Cancer Screening
    10.2    Mammography Screening
    10.3    MRI Screening
    10.4    Ultrasound Screening


    11.    United Kingdom

    11.1    United Kingdom Breast Cancer Mammography Screening Population
    11.2    United Kingdom Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
    11.3    United Kingdom Breast Cancer Screening Market

    11.3.1    Mammography Screening Market
    11.3.2    Magnetic Resonance Imaging (MRI) Screening Market
    11.3.3    Ultrasound Screening Market


    12.    France

    12.1    France Breast Cancer Mammography Screening Population
    12.2    France Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
    12.3    France Breast Cancer Screening Market

    12.3.1    Mammography Screening Market
    12.3.2    Magnetic Resonance Imaging (MRI) Screening Market
    12.3.3    Ultrasound Screening Market


    13.    Germany

    13.1    Germany Breast Cancer Mammography Screening Population
    13.2    Germany Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
    13.3    Germany Breast Cancer Screening Market

    13.3.1    Mammography Screening Market
    13.3.2    Magnetic Resonance Imaging (MRI) Screening Market
    13.3.3    Ultrasound Screening Market


    14.    Italy

    14.1    Italy Breast Cancer Mammography Screening Population
    14.2    Italy Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
    14.3    Italy Breast Cancer Screening Market

    14.3.1    Mammography Screening Market
    14.3.2    Magnetic Resonance Imaging (MRI) Screening Market
    14.3.3    Ultrasound Screening Market


    15.    Spain

    15.1    Spain Breast Cancer Mammography Screening Population
    15.2    Spain Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
    15.3    Spain Breast Cancer Screening Market

    15.3.1    Mammography Screening Market
    15.3.2    Magnetic Resonance Imaging (MRI) Screening Market
    15.3.3    Ultrasound Screening Market & Forecast


    16.    Switzerland

    16.1    Switzerland Breast Cancer Mammography Screening Population
    16.2    Switzerland Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
    16.3    Switzerland Breast Cancer Screening Market

    16.3.1    Mammography Screening Market
    16.3.2    Magnetic Resonance Imaging (MRI) Screening Market
    16.3.3    Ultrasound Screening Market


    17.    Norway

    17.1    Norway Breast Cancer Mammography Screening Population
    17.2    Norway Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
    17.3    Norway Breast Cancer Screening Market

    17.3.1    Mammography Screening Market
    17.3.2    Magnetic Resonance Imaging (MRI) Screening Market
    17.3.3    Ultrasound Screening Market


    18.    Netherlands

    18.1    Netherlands Breast Cancer Mammography Screening Population
    18.2    Netherlands Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
    18.3    Netherlands Breast Cancer Screening Market

    18.3.1    Mammography Screening Market
    18.3.2    Magnetic Resonance Imaging (MRI) Screening Market
    18.3.3    Ultrasound Screening Market


    19.    Company Analysis

    19.1    AstraZeneca

    19.1.1    Overview
    19.1.2    Recent Development
    19.1.3    Revenue

    19.2    Novartis

    19.2.1    Overview
    19.2.2    Recent Development
    19.2.3    Revenue

    19.3    Sanofi

    19.3.1    Overview
    19.3.2    Recent Development
    19.3.3    Revenue

    19.4    Pfizer

    19.4.1    Overview
    19.4.2    Recent Development
    19.4.3    Revenue

    19.5    Bayer AG

    19.5.1    Overview
    19.5.2    Recent Development
    19.5.3    Revenue

    19.6    GlaxoSmithKline plc

    19.6.1    Overview
    19.6.2    Recent Development
    19.6.3    Revenue


    List of Figures:

    Figure-01:    Europe – Breast Cancer Mammography Screening Population (Thousand), 2018 – 2022
    Figure-02:    Europe – Forecast for Breast Cancer Mammography Screening Population (Thousand), 2023 – 2028
    Figure-03:    Europe – Breast Cancer MRI & Ultrasound Screening Population (Thousand), 2018 – 2022
    Figure-04:    Europe – Forecast for Breast Cancer MRI & Ultrasound Screening Population (Thousand), 2023 – 2028
    Figure-05:    Europe – Breast Cancer Screening Market (Million US$), 2018 – 2022
    Figure-06:    Europe – Forecast for Breast Cancer Screening Market (Million US$), 2023 – 2028
    Figure-07:    Europe – Breast Cancer Mammography Screening Market (Million US$), 2018 – 2022
    Figure-08:    Europe – Forecast for Breast Cancer Mammography Screening Market (Million US$), 2023 – 2028
    Figure-09:    Europe – Breast Cancer MRI Screening Market (Million US$), 2018 – 2022
    Figure-10:    Europe – Forecast for Breast Cancer MRI Screening Market (Million US$), 2023 – 2028
    Figure-11:    Europe – Breast Cancer Ultrasound Screening Market (Million US$), 2018 – 2022
    Figure-12:    Europe – Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2023 – 2028
    Figure-13:    United Kingdom – Breast Cancer Mammography Screening Population (Thousand), 2018 – 2022
    Figure-14:    United Kingdom – Forecast for Breast Cancer Mammography Screening Population (Thousand), 2023 – 2028
    Figure-15:    United Kingdom – Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2018 – 2022
    Figure-16:    United Kingdom – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2023 – 2028
    Figure-17:    United Kingdom – Breast Cancer Mammography Screening Market (Million US$), 2018 – 2022
    Figure-18:    United Kingdom – Forecast for Breast Cancer Mammography Screening Market (Million US$), 2023 – 2028
    Figure-19:    United Kingdom – Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2018 – 2022
    Figure-20:    United Kingdom – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2023 – 2028
    Figure-21:    United Kingdom – Breast Cancer Ultrasound Screening Market (Million US$), 2018 – 2022
    Figure-22:    United Kingdom – Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2023 – 2028
    Figure-23:    France – Breast Cancer Mammography Screening Population (Thousand), 2018 – 2022
    Figure-24:    France – Forecast for Breast Cancer Mammography Screening Population (Thousand), 2023 – 2028
    Figure-25:    France – Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2018 – 2022
    Figure-26:    France – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2023 – 2028
    Figure-27:    France – Breast Cancer Mammography Screening Market (Million US$), 2018 – 2022
    Figure-28:    France – Forecast for Breast Cancer Mammography Screening Market (Million US$), 2023 – 2028
    Figure-29:    France – Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2018 – 2022
    Figure-30:    France – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2023 – 2028
    Figure-31:    France – Breast Cancer Ultrasound Screening Market (Million US$), 2018 – 2022
    Figure-32:    France – Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2023 – 2028
    Figure-33:    Germany – Breast Cancer Mammography Screening Population (Thousand), 2018 – 2022
    Figure-34:    Germany – Forecast for Breast Cancer Mammography Screening Population (Thousand), 2023 – 2028
    Figure-35:    Germany – Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2018 – 2022
    Figure-36:    Germany – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2023 – 2028
    Figure-37:    Germany – Breast Cancer Mammography Screening Market (Million US$), 2018 – 2022
    Figure-38:    Germany – Forecast for Breast Cancer Mammography Screening Market (Million US$), 2023 – 2028
    Figure-39:    Germany – Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2018 – 2022
    Figure-40:    Germany – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2023 – 2028
    Figure-41:    Germany – Breast Cancer Ultrasound Screening Market (Million US$), 2018 – 2022
    Figure-42:    Germany – Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2023 – 2028
    Figure-43:    Italy – Breast Cancer Mammography Screening Population (Thousand), 2018 – 2022
    Figure-44:    Italy – Forecast for Breast Cancer Mammography Screening Population (Thousand), 2023 – 2028
    Figure-45:    Italy – Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2018 – 2022
    Figure-46:    Italy – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2023 – 2028
    Figure-47:    Italy – Breast Cancer Mammography Screening Market (Million US$), 2018 – 2022
    Figure-48:    Italy – Forecast for Breast Cancer Mammography Screening Market (Million US$), 2023 – 2028
    Figure-49:    Italy – Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2018 – 2022
    Figure-50:    Italy – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2023 – 2028
    Figure-51:    Italy – Breast Cancer Ultrasound Screening Market (Million US$), 2018 – 2022
    Figure-52:    Italy – Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2023 – 2028
    Figure-53:    Spain – Breast Cancer Mammography Screening Population (Thousand), 2018 – 2022
    Figure-54:    Spain – Forecast for Breast Cancer Mammography Screening Population (Thousand), 2023 – 2028
    Figure-55:    Spain – Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2018 – 2022
    Figure-56:    Spain – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2023 – 2028
    Figure-57:    Spain – Breast Cancer Mammography Screening Market (Million US$), 2018 – 2022
    Figure-58:    Spain – Forecast for Breast Cancer Mammography Screening Market (Million US$), 2023 – 2028
    Figure-59:    Spain – Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2018 – 2022
    Figure-60:    Spain – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2023 – 2028
    Figure-61:    Spain – Breast Cancer Ultrasound Screening Market (Million US$), 2018 – 2022
    Figure-62:    Spain – Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2023 – 2028
    Figure-63:    Switzerland – Breast Cancer Mammography Screening Population (Thousand), 2018 – 2022
    Figure-64:    Switzerland – Forecast for Breast Cancer Mammography Screening Population (Thousand), 2023 – 2028
    Figure-65:    Switzerland – Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2018 – 2022
    Figure-66:    Switzerland – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2023 – 2028
    Figure-67:    Switzerland – Breast Cancer Mammography Screening Market (Million US$), 2018 – 2022
    Figure-68:    Switzerland – Forecast for Breast Cancer Mammography Screening Market (Million US$), 2023 – 2028
    Figure-69:    Switzerland – Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2018 – 2022
    Figure-70:    Switzerland – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2023 – 2028
    Figure-71:    Switzerland – Breast Cancer Ultrasound Screening Market (Million US$), 2018 – 2022
    Figure-72:    Switzerland – Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2023 – 2028
    Figure-73:    Norway – Breast Cancer Mammography Screening Population (Thousand), 2018 – 2022
    Figure-74:    Norway – Forecast for Breast Cancer Mammography Screening Population (Thousand), 2023 – 2028
    Figure-75:    Norway – Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2018 – 2022
    Figure-76:    Norway – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2023 – 2028
    Figure-77:    Norway – Breast Cancer Mammography Screening Market (Million US$), 2018 – 2022
    Figure-78:    Norway – Forecast for Breast Cancer Mammography Screening Market (Million US$), 2023 – 2028
    Figure-79:    Norway – Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2018 – 2022
    Figure-80:    Norway – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2023 – 2028
    Figure-81:    Norway – Breast Cancer Ultrasound Screening Market (Million US$), 2018 – 2022
    Figure-82:    Norway – Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2023 – 2028
    Figure-83:    Netherlands – Breast Cancer Mammography Screening Population (Thousand), 2018 – 2022
    Figure-84:    Netherlands – Forecast for Breast Cancer Mammography Screening Population (Thousand), 2023 – 2028
    Figure-85:    Netherlands – Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2018 – 2022
    Figure-86:    Netherlands – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2023 – 2028
    Figure-87:    Netherlands – Breast Cancer Mammography Screening Market (Million US$), 2018 – 2022
    Figure-88:    Netherlands – Forecast for Breast Cancer Mammography Screening Market (Million US$), 2023 – 2028
    Figure-89:    Netherlands – Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2018 – 2022
    Figure-90:    Netherlands – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2023 – 2028
    Figure-91:    Netherlands – Breast Cancer Ultrasound Screening Market (Million US$), 2018 – 2022
    Figure-92:    Netherlands – Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2023 – 2028
    Figure-93:    AstraZeneca – Global Revenue (Billion US$), 2018 – 2022
    Figure-94:    AstraZeneca – Forecast for Global Revenue (Billion US$), 2023 – 2028
    Figure-95:    Novartis – Global Revenue (Billion US$), 2018 – 2022
    Figure-96:    Novartis – Forecast for Global Revenue (Billion US$), 2023 – 2028
    Figure-97:    Sanofi – Global Revenue (Billion US$), 2018 – 2022
    Figure-98:    Sanofi – Forecast for Global Revenue (Billion US$), 2023 – 2028
    Figure-99:    Pfizer – Global Revenue (Billion US$), 2018 – 2022
    Figure-100:    Pfizer – Forecast for Global Revenue (Billion US$), 2023 – 2028
    Figure-101:    Bayer AG – Global Revenue (Billion US$), 2018 – 2022
    Figure-102:    Bayer AG – Forecast for Global Revenue (Billion US$), 2023 – 2028
    Figure-103:    GlaxoSmithKline plc – Global Revenue (Billion US$), 2018 – 2022
    Figure-104:    GlaxoSmithKline plc – Forecast for Global Revenue (Billion US$), 2023 – 2028


    List of Tables:

    Table-01:    Europe – Mammography Screening Population Share by Country (Percent), 2018 – 2022
    Table-02:    Europe – Forecast for Mammography Screening Population Share by Country (Percent), 2023 – 2028
    Table-03:    Europe – MRI & Ultrasound Screening Population Share by Country (Percent), 2018 – 2022
    Table-04:    Europe – Forecast for MRI & Ultrasound Screening Population Share by Country (Percent), 2023 – 2028
    Table-05:    Europe – Breast Cancer Screening Market Share by Country (Percent), 2018 – 2022
    Table-06:    Europe – Forecast for Breast Cancer Screening Market Share by Country (Percent), 2023 – 2028
    Table-07:    Europe – Mammography Screening Market Share by Country (Percent), 2018 – 2022
    Table-08:    Europe – Forecast for Mammography Screening Market Share by Country (Percent), 2023 – 2028
    Table-09:    Europe – MRI Screening Market Share by Country (Percent), 2018 – 2022
    Table-10:    Europe – Forecast for MRI Screening Market Share by Country (Percent), 2023 – 2028
    Table-11:    Europe – Ultrasound Screening Market Share by Country (Percent), 2018 – 2022
    Table-12:    Europe – Forecast for Ultrasound Screening Market Share by Country (Percent), 2023 – 2028

    • Description
      Price
    • Chapter 1 & 4     Pages : 4
      $200
    • Chapter 5     Pages : 5
      $200
    • Chapter 6     Pages : 4
      $200
    • Chapter 7     Pages : 4
      $200
    • Chapter 8     Pages : 6
      $300
    • Chapter 11     Pages : 10
      $400
    • Chapter 12     Pages : 10
      $400
    • Chapter 13     Pages : 10
      $400
    • Chapter 14     Pages : 10
      $400
    • Chapter 15     Pages : 10
      $400
    • Chapter 16     Pages : 10
      $400
    • Chapter 17     Pages : 10
      $400
    • Chapter 18     Pages : 10
      $400
    • Chapter 19.1     Pages : 5
      $150
    • Chapter 19.2     Pages : 5
      $150
    • Chapter 19.3     Pages : 5
      $150
    •      Pages : 0
      $150
    • Chapter 19.4     Pages : 5
      $150
    • Chapter 19.5     Pages : 5
      $150
    • Chapter 19.6     Pages : 5
      $150

    Related Reports